Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05548452

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

Intestinal Microbiota Transplant in Alcohol-Associated Chronic Liver Disease and Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Status
Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Virginia Commonwealth University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.

Detailed description

These intestinal microbiota transplant (IMT) capsules are an investigational drug, which means it has not been approved by the U. S. Food and Drug Administration (FDA). In this study, drug name will be compared to placebo (a look-alike inactive substance, a "sugar pill"). Participants will be randomly assigned (like the flip of a coin) to receive either IMT capsules or placebo capsules. Participants have an equal chance of being assigned to any one of the groups. In this study, participants will be asked to do the following things: 1. Visit VCU medical center up to 8 times for study visits 2. Take either IMT capsule or the placebo, depending upon which group they are assigned to; these capsules will be given twice on enrollment and after one month 3. Have blood drawn, urine and stool collected at each visit 4. Have testing done to determine the speed of brain function 5. Keep a diary at home 6. Take surveys and answer questions about general health, alcohol craving and consumption and how they are feeling. 7. Give permission for the researchers to collect information about liver disease, alcohol and mental health from medical records. Participation in this study will last up to 7 months.

Conditions

Interventions

TypeNameDescription
DRUGIntestinal Microbiota Transplant (IMT) CapsulesCapsules containing freeze-dried intestinal microbiota from healthy human donors
DRUGPlacebo CapsulesCapsules containing an inactive substance ("sugar pill")

Timeline

Start date
2022-11-21
Primary completion
2026-11-30
Completion
2026-12-30
First posted
2022-09-21
Last updated
2025-05-09

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05548452. Inclusion in this directory is not an endorsement.